Stock CMPS COMPASS PATHWAYS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Highlights COMPASS Pathways plc

Equities

CMPS

US20451W1018

Delayed Nasdaq
Other stock markets
 15:50:13 2024-05-14 EDT 		5-day change 1st Jan Change
8.19 USD +0.86% Intraday chart for COMPASS Pathways plc -4.10% -6.40%
05-09 Transcript : COMPASS Pathways plc - Shareholder/Analyst Call
05-08 Transcript : COMPASS Pathways plc, Q1 2024 Earnings Call, May 08, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
COMPASS Pathways plc Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder
CI
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for Comp360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
CI
Clarify Pharma to change name to File Forge Technology
AN
ADRs End Lower; NuCana Slides 15%
DJ
COMPASS Pathways plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
COMPASS Pathways plc Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Compass Pathways plc Enters into Research Collaboration Agreement with Hackensack Meridian Health to Develop Optimal Clinical Model for Investigational Comp360 Psilocybin Treatment, If FDA-Approved
CI
Compass Pathways, Greenbrook TMS Start Research Collaboration on Psilocybin Treatment
MT
Compass Pathways plc and Greenbrook TMS Inc. Jointly Announce They Enter into Three-Year Research Collaboration Agreement to Explore Delivery Models for Investigational COMP360 Psilocybin Treatment Upon Regulatory Approval by U.S. Food and Drug Administration
CI
COMPASS Pathways plc Announces Chief Financial Officer Changes
CI
COMPASS Pathways plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Compass Pathways plc Announces Executive Changes, Effective November 3 ,2023
CI
COMPASS Pathways plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Compass Pathways Says US Patent Office Upheld Its COMP360 Patents
MT
Numinus Wellness to Research COMP360 Psilocybin Therapy In Treatment-resistant Depression As Part of Large Phase 3 Study
MT
Compass Pathways plc Announces Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of Comp360 Psilocybin Therapy to Be Presented At Asco 2023
CI
COMPASS Pathways plc Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
COMPASS PATHWAYS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
COMPASS Pathways plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMPS Stock
  4. News COMPASS Pathways plc
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW